Changeflow GovPing Healthcare & Life Sciences Viscoelastic Hydrogel Regulates Organoid Patter...
Routine Notice Added Final

Viscoelastic Hydrogel Regulates Organoid Patterning and Vascularization

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

The USPTO has published a new patent application, US20260086081A1, detailing a viscoelastic hydrogel for regulating organoid patterning and vascularization. The application, filed on April 10, 2025, describes spinal cord models using methacrylated hyaluronic acid and dopamine-modified hyaluronic acid.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a patent application (US20260086081A1) filed with the USPTO on April 10, 2025. It discloses novel spinal cord models utilizing a cell scaffold made from methacrylated hyaluronic acid (HAMA) and dopamine-modified hyaluronic acid (HA-Cat). These models are designed to regulate organoid patterning and vascularization, and can be co-cultured with blood vessel organoids to create blood-spinal cord barrier models.

This patent application does not impose immediate regulatory obligations. However, it signals potential future developments in regenerative medicine and tissue engineering. Companies involved in biotechnology, drug development, or medical device manufacturing, particularly those focused on neural tissue engineering or organoid technology, should monitor this patent's progress and consider its implications for their research and development strategies.

Archived snapshot

Mar 27, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

VISCOELASTIC HYDROGEL REGULATION OF ORGANOID PATTERNING AND VASCULARIZATION

Application US20260086081A1 Kind: A1 Mar 26, 2026

Inventors

Changchun Zeng, Yan Li, Xingchi Chen

Abstract

Disclosed herein are spinal cord models including a cell scaffold including methacrylated hyaluronic acid (HAMA) and dopamine-modified hyaluronic acid (HA-Cat), and a spinal cord spheroid or organoid or a fragment thereof cultured on the cell scaffold. Said spinal cord spheroids or organoids or fragments thereof can be co-cultured with blood vessel spheroid organoids to form blood-spinal cord barrier models. Also disclosed herein are methods of making and using said models.

CPC Classifications

G01N 33/5082 C12N 5/0618 C12N 5/0691 C12N 5/0697 G01N 33/5023 C12N 2513/00 C12N 2533/40 C12N 2537/10

Filing Date

2025-04-10

Application No.

19175432

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 10th, 2025
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260086081A1

Who this affects

Applies to
Drug manufacturers Medical device makers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3345 Medical Device Manufacturing
Activity scope
Biotechnology Research Drug Development
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Research & Development
Compliance frameworks
GxP
Topics
Biotechnology Medical Devices

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!